REAL-BD study

Drs Chepke and Goldberg, speaking in a recap from a recent psychiatric congress, discussed exploratory results from the REAL-BD study of an every-two-month aripiprazole monohydrate formulation in adults living with bipolar I disorder. The discussion covers what the long-acting injectable data could mean for maintenance treatment of bipolar I, a condition where long-acting options are limited and adherence remains a major clinical challenge.